Loading...

China Medical & HealthCare Group

DB:SMIF
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SMIF
DB
HK$2B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

China Medical & HealthCare Group Limited, an investment holding company, primarily operates hospitals. The last earnings update was 90 days ago. More info.


Add to Portfolio Compare Print
  • China Medical & HealthCare Group has significant price volatility in the past 3 months.
SMIF Share Price and Events
7 Day Returns
10%
DB:SMIF
1.7%
DE Healthcare
1.5%
DE Market
1 Year Returns
-40.8%
DB:SMIF
-25.6%
DE Healthcare
-5.8%
DE Market
SMIF Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
China Medical & HealthCare Group (SMIF) 10% -9.4% -14.4% -40.8% -71.5% 102.6%
DE Healthcare 1.7% 0.5% -2.5% -25.6% -16.5% 33.1%
DE Market 1.5% 1.3% 2.2% -5.8% 17.6% 8.7%
1 Year Return vs Industry and Market
  • SMIF underperformed the Healthcare industry which returned -25.6% over the past year.
  • SMIF underperformed the Market in Germany which returned -5.8% over the past year.
Price Volatility
SMIF
Industry
5yr Volatility vs Market

Value

 Is China Medical & HealthCare Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of China Medical & HealthCare Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for China Medical & HealthCare Group.

DB:SMIF Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:SMIF
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.64 (1 + (1- 25%) (38.55%))
0.882
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.88
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.882 * 6.65%)
6.1%

Discounted Cash Flow Calculation for DB:SMIF using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for China Medical & HealthCare Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:SMIF DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (HKD, Millions) Source Present Value
Discounted (@ 6.1%)
2019 891.65 Est @ 42.29% 840.43
2020 1,156.20 Est @ 29.67% 1,027.16
2021 1,397.12 Est @ 20.84% 1,169.88
2022 1,601.86 Est @ 14.65% 1,264.26
2023 1,767.28 Est @ 10.33% 1,314.67
2024 1,896.23 Est @ 7.3% 1,329.56
2025 1,994.39 Est @ 5.18% 1,318.04
2026 2,068.02 Est @ 3.69% 1,288.18
2027 2,122.87 Est @ 2.65% 1,246.37
2028 2,163.74 Est @ 1.93% 1,197.38
Present value of next 10 years cash flows HK$11,995.94
DB:SMIF DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= HK$2,163.74 × (1 + 0.23%) ÷ (6.1% – 0.23%)
HK$36,960.30
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= HK$36,960.30 ÷ (1 + 6.1%)10
HK$20,453.26
DB:SMIF Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= HK$11,995.94 + HK$20,453.26
HK$32,449.20
Equity Value per Share
(HKD)
= Total value / Shares Outstanding
= HK$32,449.20 / 14,480.07
HK$2.24
DB:SMIF Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:SMIF represents 0.1x of SEHK:383
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.1x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (HKD) x Listing Adjustment Factor
= HK$ 2.24 x 0.1
€0.22
Value per share (EUR) From above. €0.22
Current discount Discount to share price of €0.02
= -1 x (€0.02 - €0.22) / €0.22
93.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price China Medical & HealthCare Group is available for.
Intrinsic value
>50%
Share price is €0.0154 vs Future cash flow value of €0.2241
Current Discount Checks
For China Medical & HealthCare Group to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • China Medical & HealthCare Group's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • China Medical & HealthCare Group's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for China Medical & HealthCare Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are China Medical & HealthCare Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:SMIF PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in HKD HK$0.00
SEHK:383 Share Price ** SEHK (2019-06-25) in HKD HK$0.15
Germany Healthcare Industry PE Ratio Median Figure of 10 Publicly-Listed Healthcare Companies 29.06x
Germany Market PE Ratio Median Figure of 425 Publicly-Listed Companies 19.8x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of China Medical & HealthCare Group.

DB:SMIF PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:383 Share Price ÷ EPS (both in HKD)

= 0.15 ÷ 0.00

-43.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • China Medical & HealthCare Group is loss making, we can't compare its value to the DE Healthcare industry average.
  • China Medical & HealthCare Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does China Medical & HealthCare Group's expected growth come at a high price?
Raw Data
DB:SMIF PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -43.02x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.42x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for China Medical & HealthCare Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on China Medical & HealthCare Group's assets?
Raw Data
DB:SMIF PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in HKD HK$0.12
SEHK:383 Share Price * SEHK (2019-06-25) in HKD HK$0.15
Germany Healthcare Industry PB Ratio Median Figure of 12 Publicly-Listed Healthcare Companies 1.59x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.8x
DB:SMIF PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:383 Share Price ÷ Book Value per Share (both in HKD)

= 0.15 ÷ 0.12

1.23x

* Primary Listing of China Medical & HealthCare Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • China Medical & HealthCare Group is good value based on assets compared to the DE Healthcare industry average.
X
Value checks
We assess China Medical & HealthCare Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. China Medical & HealthCare Group has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is China Medical & HealthCare Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Medical & HealthCare Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
8.7%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is China Medical & HealthCare Group expected to grow at an attractive rate?
  • Unable to compare China Medical & HealthCare Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare China Medical & HealthCare Group's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare China Medical & HealthCare Group's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:SMIF Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 8.7%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:SMIF Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in HKD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:SMIF Future Estimates Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:SMIF Past Financials Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income *
2018-12-31 1,139 705 -52
2018-09-30 1,120 839 -94
2018-06-30 1,101 973 -137
2018-03-31 1,115 495 -198
2017-12-31 1,130 16 -258
2017-09-30 1,207 100 -165
2017-06-30 1,284 184 -72
2017-03-31 1,791 296 -143
2016-12-31 2,297 408 -214
2016-09-30 2,349 88 -498
2016-06-30 2,400 -232 -783
2016-03-31 1,787 -375

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if China Medical & HealthCare Group is high growth as no earnings estimate data is available.
  • Unable to determine if China Medical & HealthCare Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:SMIF Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from China Medical & HealthCare Group Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SMIF Future Estimates Data
Date (Data in HKD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:SMIF Past Financials Data
Date (Data in HKD Millions) EPS *
2018-12-31 0.00
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.02
2017-09-30 -0.01
2017-06-30 0.00
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.04
2016-06-30 -0.06
2016-03-31 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if China Medical & HealthCare Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether China Medical & HealthCare Group is trading at China Medical & HealthCare Group'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. China Medical & HealthCare Group's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. China Medical & HealthCare Group's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess China Medical & HealthCare Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
China Medical & HealthCare Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has China Medical & HealthCare Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare China Medical & HealthCare Group's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • China Medical & HealthCare Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare China Medical & HealthCare Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare China Medical & HealthCare Group's 1-year growth to the DE Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
China Medical & HealthCare Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from China Medical & HealthCare Group Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SMIF Past Revenue, Cash Flow and Net Income Data
Date (Data in HKD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1,139.20 -51.84 243.30
2018-09-30 1,119.92 -94.48 245.68
2018-06-30 1,100.64 -137.11 248.06
2018-03-31 1,115.23 -197.65 248.51
2017-12-31 1,129.81 -258.19 248.95
2017-09-30 1,207.08 -165.00 245.02
2017-06-30 1,284.34 -71.81 241.08
2017-03-31 1,790.90 -142.78 251.12
2016-12-31 2,297.46 -213.75 261.15
2016-09-30 2,348.60 -498.45 243.02
2016-06-30 2,399.74 -783.16 224.89
2016-03-31 1,787.44 -375.28 194.95
2015-12-31 1,175.15 32.60 165.02
2015-09-30 945.08 130.52 152.85
2015-06-30 715.02 228.44 140.69
2015-03-31 858.86 232.68 197.07
2014-12-31 1,002.70 236.93 253.45
2014-09-30 1,049.55 582.42 232.24
2014-06-30 1,096.40 927.91 211.02
2013-12-31 219.10 -363.27 -4.01
2013-09-30 80.14 -540.76 11.73
2013-06-30 -58.81 -718.25 27.47
2013-03-31 411.97 -442.78 95.49
2012-12-31 188.03 -104.84 79.16
2012-09-30 117.37 -318.13 63.19
2012-06-30 46.70 -531.43 47.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if China Medical & HealthCare Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • China Medical & HealthCare Group used its assets less efficiently than the DE Healthcare industry average last year based on Return on Assets.
  • It is difficult to establish if China Medical & HealthCare Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess China Medical & HealthCare Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
China Medical & HealthCare Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is China Medical & HealthCare Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up China Medical & HealthCare Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • China Medical & HealthCare Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • China Medical & HealthCare Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of China Medical & HealthCare Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from China Medical & HealthCare Group Company Filings, last reported 5 months ago.

DB:SMIF Past Debt and Equity Data
Date (Data in HKD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,804.21 845.03 408.33
2018-09-30 1,804.21 845.03 408.33
2018-06-30 1,818.84 825.50 713.14
2018-03-31 1,818.84 825.50 713.14
2017-12-31 2,024.42 1,510.77 528.59
2017-09-30 2,024.42 1,510.77 528.59
2017-06-30 2,042.03 1,826.43 1,701.78
2017-03-31 2,042.03 1,826.43 1,701.78
2016-12-31 2,197.03 2,163.01 779.54
2016-09-30 2,197.03 2,163.01 779.54
2016-06-30 2,078.31 2,634.03 2,022.30
2016-03-31 2,078.31 2,634.03 2,022.30
2015-12-31 2,624.25 2,484.52 990.31
2015-09-30 2,624.25 2,484.52 990.31
2015-06-30 2,011.43 1,874.13 2,071.75
2015-03-31 2,011.43 1,874.13 2,071.75
2014-12-31 1,581.97 850.26 205.82
2014-09-30 1,581.97 850.26 205.82
2014-06-30 2,264.93 2,935.36 2,360.86
2013-12-31 1,834.76 3,180.76 1,776.40
2013-09-30 1,834.76 3,180.76 1,776.40
2013-06-30 1,490.94 2,710.88 1,509.55
2013-03-31 1,490.94 2,710.88 1,509.55
2012-12-31 2,314.90 2,628.47 1,695.48
2012-09-30 2,314.90 2,628.47 1,695.48
2012-06-30 1,846.95 1,505.10 1,334.05
  • China Medical & HealthCare Group's level of debt (47.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (178.3% vs 47.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making China Medical & HealthCare Group has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making China Medical & HealthCare Group has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -102.2% per year.
X
Financial health checks
We assess China Medical & HealthCare Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. China Medical & HealthCare Group has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is China Medical & HealthCare Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from China Medical & HealthCare Group dividends.
If you bought €2,000 of China Medical & HealthCare Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate China Medical & HealthCare Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate China Medical & HealthCare Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:SMIF Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:SMIF Future Dividends Estimate Data
Date (Data in HK$) Dividend per Share (annual) Avg. No. Analysts
DB:SMIF Past Annualized Dividends Data
Date (Data in HK$) Dividend per share (annual) Avg. Yield (%)
2016-03-30 0.000 0.000
2016-02-24 0.000 0.000
2015-10-29 0.000 0.000
2015-09-24 0.000 0.000
2014-12-03 0.003 1.061
2013-03-25 0.000 0.000
2013-02-27 0.000 0.000
2012-10-29 0.000 0.000
2012-09-20 0.000 0.000
2011-09-22 0.002 3.803
2010-04-13 0.002 3.006
2009-09-25 0.000 0.000
2009-09-14 0.000 0.000
2009-04-23 0.000 0.000
2008-09-18 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as China Medical & HealthCare Group has not reported any payouts.
  • Unable to verify if China Medical & HealthCare Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of China Medical & HealthCare Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as China Medical & HealthCare Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess China Medical & HealthCare Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can China Medical & HealthCare Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. China Medical & HealthCare Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of China Medical & HealthCare Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • China Medical & HealthCare Group has no CEO, or we have no data on them.
Management Team

Sok Un Chong

TITLE
Deputy Chairman
COMPENSATION
HK$473K
AGE
64

Muk Yin Kong

TITLE
Executive Director
COMPENSATION
HK$2M
AGE
52

Meibao Guo

TITLE
Executive Director
AGE
45

Haiying Zhou

TITLE
Executive Director
AGE
48

Janet Ada Fung

TITLE
Company Secretary
AGE
55
Board of Directors Tenure

Average tenure and age of the China Medical & HealthCare Group board of directors in years:

1.6
Average Tenure
56.5
Average Age
  • The average tenure for the China Medical & HealthCare Group board of directors is less than 3 years, this suggests a new board.
Board of Directors

Liye Zhou

TITLE
Chairman
AGE
55
TENURE
0.5 yrs

Sok Un Chong

TITLE
Deputy Chairman
COMPENSATION
HK$473K
AGE
64
TENURE
3.5 yrs

Muk Yin Kong

TITLE
Executive Director
COMPENSATION
HK$2M
AGE
52
TENURE
17.1 yrs

Meibao Guo

TITLE
Executive Director
AGE
45
TENURE
0.8 yrs

Haiying Zhou

TITLE
Executive Director
AGE
48
TENURE
0.5 yrs

Xiaoning Xia

TITLE
Independent Non-Executive Director
COMPENSATION
HK$220K
AGE
58
TENURE
2.5 yrs

Albert Wong

TITLE
Independent Non-Executive Director
AGE
66
TENURE
0.5 yrs

John Wong

TITLE
Non-Executive Director
COMPENSATION
HK$2M
AGE
74
TENURE
17.3 yrs

Jian Zhang

TITLE
Independent Non-Executive Director
COMPENSATION
HK$100K
AGE
76
TENURE
12.7 yrs

Lisa Yang

TITLE
Independent Non-Executive Director
AGE
51
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. Jun 19 Buy Tian An China Investments Company Limited Company 12. Jun 19 12. Jun 19 5,220,000 €0.02 €82,446
13. Jun 19 Buy Tian An China Investments Company Limited Company 10. Jun 19 10. Jun 19 550,000 €0.02 €8,679
12. Jun 19 Buy Tian An China Investments Company Limited Company 06. Jun 19 06. Jun 19 5,680,000 €0.02 €91,610
06. Jun 19 Buy Tian An China Investments Company Limited Company 03. Jun 19 03. Jun 19 450,000 €0.02 €7,380
03. Jun 19 Buy Tian An China Investments Company Limited Company 29. May 19 29. May 19 3,000,000 €0.02 €49,800
31. May 19 Buy Tian An China Investments Company Limited Company 28. May 19 28. May 19 180,000 €0.02 €2,770
29. May 19 Buy Tian An China Investments Company Limited Company 24. May 19 24. May 19 8,060,000 €0.02 €141,816
30. May 19 Buy Tian An China Investments Company Limited Company 27. May 19 27. May 19 200,000,000 €0.02 €3,414,778
28. May 19 Buy Tian An China Investments Company Limited Company 23. May 19 23. May 19 6,290,000 €0.02 €114,817
27. May 19 Buy Tian An China Investments Company Limited Company 22. May 19 22. May 19 11,330,000 €0.02 €200,480
24. May 19 Buy Tian An China Investments Company Limited Company 21. May 19 21. May 19 11,550,000 €0.02 €192,289
22. May 19 Buy Tian An China Investments Company Limited Company 17. May 19 17. May 19 5,940,000 €0.02 €108,073
23. May 19 Buy Tian An China Investments Company Limited Company 20. May 19 20. May 19 5,560,000 €0.02 €96,624
16. May 19 Buy Tian An China Investments Company Limited Company 10. May 19 10. May 19 2,360,000 €0.02 €44,531
21. May 19 Buy Tian An China Investments Company Limited Company 16. May 19 16. May 19 5,950,000 €0.02 €108,318
20. May 19 Buy Tian An China Investments Company Limited Company 15. May 19 15. May 19 2,680,000 €0.02 €49,035
17. May 19 Buy Tian An China Investments Company Limited Company 14. May 19 14. May 19 1,440,000 €0.02 €26,123
15. May 19 Buy Tian An China Investments Company Limited Company 09. May 19 09. May 19 180,000 €0.02 €3,308
14. May 19 Buy Tian An China Investments Company Limited Company 08. May 19 08. May 19 1,560,000 €0.02 €29,319
16. Apr 19 Buy Tian An China Investments Company Limited Company 11. Apr 19 11. Apr 19 170,000 €0.02 €3,462
12. Apr 19 Buy Tian An China Investments Company Limited Company 09. Apr 19 09. Apr 19 520,000 €0.02 €10,591
11. Apr 19 Buy Tian An China Investments Company Limited Company 08. Apr 19 08. Apr 19 5,000,000 €0.02 €101,883
09. Apr 19 Buy Tian An China Investments Company Limited Company 03. Apr 19 03. Apr 19 10,890,000 €0.02 €234,876
03. Apr 19 Buy Tian An China Investments Company Limited Company 29. Mar 19 29. Mar 19 7,540,000 €0.02 €148,827
29. Mar 19 Buy Tian An China Investments Company Limited Company 26. Mar 19 26. Mar 19 1,090,000 €0.02 €22,144
26. Mar 19 Buy Tian An China Investments Company Limited Company 21. Mar 19 21. Mar 19 250,000 €0.02 €4,998
22. Mar 19 Buy Tian An China Investments Company Limited Company 19. Mar 19 19. Mar 19 510,000 €0.02 €10,532
25. Mar 19 Buy Tian An China Investments Company Limited Company 20. Mar 19 20. Mar 19 4,340,000 €0.02 €87,059
21. Mar 19 Buy Tian An China Investments Company Limited Company 18. Mar 19 18. Mar 19 820,000 €0.02 €17,021
20. Mar 19 Buy Tian An China Investments Company Limited Company 15. Mar 19 15. Mar 19 2,100,000 €0.02 €44,185
19. Mar 19 Buy Tian An China Investments Company Limited Company 14. Mar 19 14. Mar 19 2,270,000 €0.02 €47,589
13. Mar 19 Buy Tian An China Investments Company Limited Company 08. Mar 19 08. Mar 19 295,010,000 €0.02 €6,684,966
06. Mar 19 Buy Tian An China Investments Company Limited Company 01. Mar 19 01. Mar 19 100,000,000 €0.02 €2,239,701
28. Dec 18 Buy Tian An China Investments Company Limited Company 21. Dec 18 21. Dec 18 110,000 €0.02 €2,314
27. Dec 18 Buy Tian An China Investments Company Limited Company 20. Dec 18 20. Dec 18 460,000 €0.02 €9,521
21. Dec 18 Buy Tian An China Investments Company Limited Company 18. Dec 18 18. Dec 18 11,130,000 €0.02 €223,663
20. Dec 18 Buy Tian An China Investments Company Limited Company 17. Dec 18 17. Dec 18 90,000 €0.02 €1,858
19. Dec 18 Buy Tian An China Investments Company Limited Company 14. Dec 18 14. Dec 18 3,870,000 €0.02 €80,283
12. Dec 18 Buy Tian An China Investments Company Limited Company 07. Dec 18 07. Dec 18 24,990,000 €0.02 €514,652
10. Dec 18 Buy Tian An China Investments Company Limited Company 05. Dec 18 05. Dec 18 5,110,000 €0.02 €109,002
07. Dec 18 Buy Tian An China Investments Company Limited Company 04. Dec 18 04. Dec 18 2,920,000 €0.02 €62,607
30. Nov 18 Buy Tian An China Investments Company Limited Company 27. Nov 18 27. Nov 18 9,150,000 €0.02 €196,619
26. Nov 18 Buy Tian An China Investments Company Limited Company 21. Nov 18 21. Nov 18 610,000 €0.02 €12,981
23. Nov 18 Buy Tian An China Investments Company Limited Company 20. Nov 18 20. Nov 18 430,000 €0.02 €9,300
20. Nov 18 Buy Tian An China Investments Company Limited Company 14. Nov 18 14. Nov 18 10,000 €0.02 €218
15. Nov 18 Buy Tian An China Investments Company Limited Company 12. Nov 18 12. Nov 18 60,000 €0.02 €1,348
14. Nov 18 Buy Tian An China Investments Company Limited Company 09. Nov 18 09. Nov 18 15,000,000 €0.02 €334,908
13. Nov 18 Buy Tian An China Investments Company Limited Company 08. Nov 18 08. Nov 18 18,920,000 €0.02 €425,554
12. Nov 18 Buy Tian An China Investments Company Limited Company 07. Nov 18 07. Nov 18 6,100,000 €0.02 €136,492
05. Oct 18 Buy Tian An China Investments Company Limited Company 02. Oct 18 02. Oct 18 10,000,000 €0.03 €287,001
04. Oct 18 Buy Tian An China Investments Company Limited Company 28. Sep 18 28. Sep 18 5,000,000 €0.03 €142,992
03. Oct 18 Buy Tian An China Investments Company Limited Company 27. Sep 18 27. Sep 18 80,000 €0.03 €2,281
02. Oct 18 Buy Tian An China Investments Company Limited Company 26. Sep 18 26. Sep 18 5,000,000 €0.03 €141,006
28. Sep 18 Buy Tian An China Investments Company Limited Company 24. Sep 18 24. Sep 18 17,130,000 €0.03 €484,019
27. Sep 18 Buy Tian An China Investments Company Limited Company 21. Sep 18 21. Sep 18 9,970,000 €0.03 €278,289
26. Sep 18 Buy Tian An China Investments Company Limited Company 20. Sep 18 20. Sep 18 3,490,000 €0.03 €95,594
24. Sep 18 Buy Tian An China Investments Company Limited Company 19. Sep 18 19. Sep 18 8,810,000 €0.03 €240,499
21. Sep 18 Buy Tian An China Investments Company Limited Company 18. Sep 18 18. Sep 18 2,880,000 €0.03 €77,671
20. Sep 18 Buy Tian An China Investments Company Limited Company 17. Sep 18 17. Sep 18 2,740,000 €0.03 €74,266
19. Sep 18 Buy Tian An China Investments Company Limited Company 14. Sep 18 14. Sep 18 2,190,000 €0.03 €56,912
18. Sep 18 Buy Tian An China Investments Company Limited Company 13. Sep 18 13. Sep 18 660,000 €0.02 €15,878
17. Sep 18 Buy Tian An China Investments Company Limited Company 12. Sep 18 12. Sep 18 16,660,000 €0.02 €403,047
14. Sep 18 Buy Tian An China Investments Company Limited Company 11. Sep 18 11. Sep 18 4,000,000 €0.03 €102,233
12. Sep 18 Buy Tian An China Investments Company Limited Company 07. Sep 18 07. Sep 18 50,000 €0.03 €1,293
11. Sep 18 Buy Tian An China Investments Company Limited Company 06. Sep 18 06. Sep 18 60,000 €0.03 €1,546
10. Sep 18 Buy Tian An China Investments Company Limited Company 05. Sep 18 05. Sep 18 2,010,000 €0.03 €53,472
07. Sep 18 Buy Tian An China Investments Company Limited Company 04. Sep 18 04. Sep 18 3,190,000 €0.03 €84,769
X
Management checks
We assess China Medical & HealthCare Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. China Medical & HealthCare Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

China Medical & HealthCare Group Limited, an investment holding company, primarily operates hospitals. It operates through six segments: Healthcare, Eldercare, Property Development, Property Investment, Financial Services, and Securities Trading and Investments. The company is also involved in the property development of independent living units; and project management of health campus with a focus on elderly care and retirement community comprising elderly nursing homes, service apartments, and independent living units, as well as a shopping mall, retail shops, and club hall facilities. In addition, it develops and sells properties and land; leases residential and office properties; and provides money lending, financial and strategic investment, and healthcare services. Further, the company is involved in the medical equipment and related supplies. Additionally, it invests and trades in securities. The company operates in the People’s Republic of China and Hong Kong. It is also involved in the trading of securities listed in overseas exchange. The company was formerly known as COL Capital Limited and changed its name to China Medical & HealthCare Group Limited in February 2016. The company is headquartered in Wanchai, Hong Kong.

Details
Name: China Medical & HealthCare Group Limited
SMIF
Exchange: DB
Founded:
HK$250,794,669
14,480,072,773
Website: http://www.cmhg.com.hk
Address: China Medical & HealthCare Group Limited
China Online Centre,
47th Floor,
Wanchai,
Hong Kong
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 383 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 02. Jan 1992
OTCPK COLR.F Ordinary Shares Pink Sheets LLC US USD 02. Jan 1992
DB SMIF Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
Number of employees
Current staff
Staff numbers
2,321
China Medical & HealthCare Group employees.
Industry
Health Care Facilities
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/26 02:55
End of day share price update: 2019/06/25 00:00
Last estimates confirmation: 2018/09/27
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.